Highlighting latest clinical findings, including comparative efficacy for ocular itch relief between Pataday Once Daily Relief Extra Strength and an oral antihistamine Forthcoming innovations
Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
Alcon Inc. Investors: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
Alcon Inc. Investors: Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S.
1
The drop, formerly prescribed as Pazeo, joins Alcon s over-the-counter ocular allergy portfolio to meet a variety of patient needs
The expansion of the Pataday portfolio of products will strengthen Alcon s leadership position in the U.S. eye allergy OTC market
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Pataday
Once Daily Relief Extra Strength (
olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following its 2020 approval by the Food and Drug Administration (FDA) for sale over-the-counter (OTC). As Alcon s third Rx-to-OTC switch in the past twelve months, Pataday Once Daily Relief Extra Strength joins the #1 selling OTC eye allergy relief brand and is poised to help the company maintain its leadership position in the ocular all